AbCellera Biologics Inc. Selling and Marketing Expense
AbCellera Biologics Inc. (ABCL) reported Selling and Marketing Expense of $2.91 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2025-11-06
- AbCellera Biologics Inc. selling and marketing expense for the quarter ending 2025-09-30 was $2.91M, a 7.30% decline year-over-year.
- AbCellera Biologics Inc. selling and marketing expense for the quarter ending 2025-06-30 was $3.01M, a 4.05% decline year-over-year.
- AbCellera Biologics Inc. selling and marketing expense for the quarter ending 2025-03-31 was $2.84M, a 15.54% decline year-over-year.
- AbCellera Biologics Inc. selling and marketing expense for the quarter ending 2024-12-31 was $3.14M, a 1.42% increase year-over-year.
- AbCellera Biologics Inc. selling and marketing expense for fiscal 2024 was $12.78M, a 9.88% decline from fiscal 2023.
- AbCellera Biologics Inc. selling and marketing expense for fiscal 2023 was $14.18M, a 25.82% increase from fiscal 2022.
- AbCellera Biologics Inc. selling and marketing expense for fiscal 2022 was $11.27M, a 63.03% increase from fiscal 2021.
- AbCellera Biologics Inc. selling and marketing expense for fiscal 2021 was $6.91M, a 79.93% increase from fiscal 2020.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $2.91M 10-Q · filed 2025-11-06 | $5.92M derived: sum of 2 quarters · filed 2025-11-06 | $8.76M 10-Q · filed 2025-11-06 | $11.90M derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | $3.01M 10-Q · filed 2025-08-07 | $5.85M 10-Q · filed 2025-08-07 | $8.99M derived: sum of 3 quarters · filed 2025-08-07 | $12.13M derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-03-31 | $2.84M 10-Q · filed 2025-05-08 | $5.99M derived: sum of 2 quarters · filed 2025-05-08 | $9.12M derived: sum of 3 quarters · filed 2025-11-06 | $12.26M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.28M derived: sum of 2 quarters · filed 2025-11-06 | $9.41M derived: sum of 3 quarters · filed 2025-11-06 | $12.78M 10-K · filed 2025-02-27 |
| 2024-09-30 | $3.13M 10-Q · filed 2025-11-06 | $6.27M derived: sum of 2 quarters · filed 2025-11-06 | $9.63M 10-Q · filed 2025-11-06 | $12.74M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.14M 10-Q · filed 2025-08-07 | $6.50M 10-Q · filed 2025-08-07 | $9.60M derived: sum of 3 quarters · filed 2025-08-07 | $13.07M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $3.37M 10-Q · filed 2025-05-08 | $6.46M derived: sum of 2 quarters · filed 2025-05-08 | $9.93M derived: sum of 3 quarters · filed 2025-05-08 | $13.77M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.57M derived: sum of 2 quarters · filed 2025-02-27 | $10.41M derived: sum of 3 quarters · filed 2025-02-27 | $14.18M 10-K · filed 2025-02-27 |
| 2023-09-30 | $3.47M 10-Q · filed 2024-11-04 | $7.31M derived: sum of 2 quarters · filed 2024-11-04 | $11.08M 10-Q · filed 2024-11-04 | $13.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.84M 10-Q · filed 2024-08-06 | $7.61M 10-Q · filed 2024-08-06 | $10.30M derived: sum of 3 quarters · filed 2025-02-27 | $13.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.77M 10-Q · filed 2024-05-07 | $6.46M derived: sum of 2 quarters · filed 2025-02-27 | $9.55M derived: sum of 3 quarters · filed 2025-02-27 | $12.67M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.78M derived: sum of 2 quarters · filed 2025-02-27 | $8.90M derived: sum of 3 quarters · filed 2025-02-27 | $11.27M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.09M 10-Q · filed 2023-11-02 | $6.21M derived: sum of 2 quarters · filed 2023-11-02 | $8.58M 10-Q · filed 2023-11-02 | $10.41M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $3.12M 10-Q · filed 2023-08-03 | $5.49M 10-Q · filed 2023-08-03 | $7.32M derived: sum of 3 quarters · filed 2024-02-20 | $8.53M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $2.37M 10-Q · filed 2023-05-04 | $4.20M derived: sum of 2 quarters · filed 2024-02-20 | $5.41M derived: sum of 3 quarters · filed 2024-02-20 | $6.71M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $3.04M derived: sum of 2 quarters · filed 2024-02-20 | $4.34M derived: sum of 3 quarters · filed 2024-02-20 | $6.91M 10-K · filed 2024-02-20 |
| 2021-09-30 | $1.22M 10-Q · filed 2022-11-08 | $2.51M derived: sum of 2 quarters · filed 2022-11-08 | $5.09M 10-Q · filed 2022-11-08 | $7.32M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $1.29M 10-Q · filed 2022-08-09 | $3.87M 10-Q · filed 2022-08-09 | $6.11M derived: sum of 3 quarters · filed 2023-02-21 | $6.73M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $2.58M 10-Q · filed 2022-05-10 | $4.81M derived: sum of 2 quarters · filed 2023-02-21 | $5.44M derived: sum of 3 quarters · filed 2023-02-21 | $5.98M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $2.86M derived: sum of 2 quarters · filed 2023-02-21 | $3.40M derived: sum of 3 quarters · filed 2023-02-21 | $3.84M 10-K · filed 2023-02-21 |
| 2020-09-30 | $626.00K 10-Q · filed 2021-11-10 | $1.17M derived: sum of 2 quarters · filed 2021-11-10 | $1.61M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $547.00K 10-Q · filed 2021-08-13 | $984.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $437.00K 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $1.26M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |